Overview

A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine

Status:
Completed

Trial end date:
2020-07-01

Target enrollment:

Participant gender:

Summary

This is an open-label, randomized, active comparator, multicenter, international Phase 3 study of NKTR-102 versus TPC in patients with metastatic breast cancer who have stable brain metastases and have been previously treated with an anthracycline, a taxane, and capecitabine in either the adjuvant or metastatic setting (prior anthracycline may be omitted if medically appropriate or contraindicated for the patient).

Phase:

Phase 3

Details

Lead Sponsor:

Nektar Therapeutics

Treatments:

Albumin-Bound Paclitaxel
Capecitabine
Docetaxel
Etirinotecan pegol
Gemcitabine
Paclitaxel
Taxane
Vinorelbine